Key facts
- This page summarizes Anna Trask's Form 4 filing for Decibel Therapeutics, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 28 Feb 2022, 15:38.
Anna Trask - 25 Feb 2022 Form 4 Insider Report for Decibel Therapeutics, Inc.
- Signature
- /s/ Elisabeth Leiderman, Attorney-in-Fact
- Issuer symbol
- N/A
- Transactions as of
- 25 Feb 2022
- Net transaction value
- $0
- Form type
- 4
- Filing time
- 28 Feb 2022, 15:38:06 UTC
- Previous filing
- 04 Jan 2022
- Next filing
- 30 Jan 2023
- SEC filing
- View on sec.gov
Reporting owner
Issuer context
Transaction snapshot
SEC evidence
Key filing fact
Anna Trask filed Form 4 for Decibel Therapeutics, Inc. on 28 Feb 2022.
Change
- Previous filing in this sequence was filed on 04 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
DBTX
transaction
Derivative
Stock Options (right to buy)
Award
- Transaction value
- $0
- Shares
- +52,500
- Change %
- Price
- $0.000000
- Shares after
- 52,500
- Date
- 25 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 52,500
- Exercise price
- $3.50
- Footnotes
- F1
* indicates a reported price that failed the local validity check.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The option was granted on February 25, 2022. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 25, 2023 and with respect to the remainder in 36 equal monthly installments thereafter through February 25, 2026. |
Remarks:
Chief Human Resources Officer